Med Dev Corp., a Delaware-based startup, has raised $775,000 from private investors to reduce hospital-acquired infections or surgical-site infections. Med Dev’s devices all attempt a non-antibiotic approach to eradicating nasal MRSA colonization, which is “the No. 1 predictor” for SSIs in orthopedic, cardiac and GI surgeries, according to Chairman Mike Martin.
The company still seeks $2,225,000.
He said the money will go toward additional testing and expenses for U.S. Food and Drug Administration approval. He hopes to be selling product by Jan. 1, 2014. The company incorporated in 2012.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Martin said the company has commitments for the remaining $225,000 it sought, and Med Dev is now in its second round of mezzanine funding.
According to the regulatory filing, Med Dev’s officers include Martin, William Peters, Michael Moore and Thomas Finley.
